学科与关键词
关键词
savolitinibMET exon 14NSCLC
- SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLCZhou, Q.; Li, J.; Wang, J.; Yang, L.; Fang, J.; Dong, X.; Yi, T.; Min, X.; Xu, F.; Chen, J.; Zhong, D.; Bai, J.; Liu, L.; Zeng, A.; Tang, J.; Wu, H.; Luo, X.; Yu, J.; Su, W.; Wu, Y. -L.
- Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
- Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinibZhang, Li; Wang, Yongsheng; Lin, Lizhu; Yu, Yongfeng; Lu, Shun*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231216089.
